The effects of Paxlovid on glycolipid immunometabolism in the patients
with non-severe SARS-CoV-2 infection
Abstract
A wave of SARS-CoV-2 infection speedily emerged in Shanghai, China,
since late February 2022. Paxlovid is a therapeutic hybrid of different
compounds and a novel SARS-CoV-2 protease inhibitor by blocking an
enzyme required for viral protein synthesis. It could reduce the risk of
hospitalization or death by 89% as well as being benefit for
immunocompromised and severe COVID-19 patients. Our registry study
indicated that the days of viral elimination and inflammation factors,
such as IL-6, IL-10 and interferon-α levels could be lowered by
paxlovid. Days of viral elimination may be associated with fasting blood
glucose, NK cells count, interferon-α levels. Lipids profiles should be
monitored before and after treatment of paxlovid, especially for those
who have uncontrolled lipid disorder.